BR9914892A - Composição farmacêutica, contendo fragmentos de um dna de codificação de proteìna antigênica dotado com efeito antitumor - Google Patents

Composição farmacêutica, contendo fragmentos de um dna de codificação de proteìna antigênica dotado com efeito antitumor

Info

Publication number
BR9914892A
BR9914892A BR9914892-7A BR9914892A BR9914892A BR 9914892 A BR9914892 A BR 9914892A BR 9914892 A BR9914892 A BR 9914892A BR 9914892 A BR9914892 A BR 9914892A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
antigenic protein
dna encoding
antitumor effect
containing fragments
Prior art date
Application number
BR9914892-7A
Other languages
English (en)
Inventor
Dino Parente
Anna Maria Di Massimo
Rita De Santis
Original Assignee
Menarini Ricerche Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Menarini Ricerche Spa filed Critical Menarini Ricerche Spa
Publication of BR9914892A publication Critical patent/BR9914892A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Patente de Invenção: <B>"COMPOSIçãO FARMACêUTICA, CONTENDO FRAGMENTOS DE UM DNA DE CODIFICAçãO DE PROTEìNA ANTIGêNICA DOTADO COM EFEITO ANTITUMOR"<D>. é proporcionada aqui uma composição farmacêutica contendo uma ou mais moléculas de DNA codificando fragmentos de uma proteína superexpressa em células de tumor, a fim de induzir uma resposta imunológica específica para Ag, antitumor, em associação com excipientes e adjuntos adequados.
BR9914892-7A 1998-10-30 1999-10-18 Composição farmacêutica, contendo fragmentos de um dna de codificação de proteìna antigênica dotado com efeito antitumor BR9914892A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1998MI002330A IT1303683B1 (it) 1998-10-30 1998-10-30 Composizione farmaceutiche ad azione antitumorale contenente dnacodificante per frammenti di una proteina antigenica.
PCT/EP1999/007874 WO2000025827A2 (en) 1998-10-30 1999-10-18 Dna molecules encoding muc-1 and use thereof in tumor vaccination

Publications (1)

Publication Number Publication Date
BR9914892A true BR9914892A (pt) 2001-07-17

Family

ID=11380969

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9914892-7A BR9914892A (pt) 1998-10-30 1999-10-18 Composição farmacêutica, contendo fragmentos de um dna de codificação de proteìna antigênica dotado com efeito antitumor

Country Status (19)

Country Link
EP (1) EP1124956A2 (pt)
JP (1) JP2002528519A (pt)
CN (1) CN1324406A (pt)
AR (1) AR020927A1 (pt)
AU (1) AU1152200A (pt)
BG (1) BG105458A (pt)
BR (1) BR9914892A (pt)
CA (1) CA2348745A1 (pt)
CO (1) CO5231134A1 (pt)
CZ (1) CZ20011521A3 (pt)
EA (1) EA200100395A1 (pt)
HU (1) HUP0103784A2 (pt)
IT (1) IT1303683B1 (pt)
MX (1) MXPA01004186A (pt)
PE (1) PE20001287A1 (pt)
PL (1) PL348156A1 (pt)
SK (1) SK5712001A3 (pt)
TR (1) TR200101141T2 (pt)
WO (1) WO2000025827A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548643B1 (en) 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
JP2003533181A (ja) * 2000-02-01 2003-11-11 ジ・オースティン・リサーチ・インスティテュート ムチン−１誘導抗原および免疫療法におけるその使用
DE60140461D1 (de) * 2000-09-11 2009-12-24 Genzyme Corp Muc1 extrazelluläre domäne und zusammensetzungen für krebsbehandlung, und davon abgeleitete verfahren
EP1958642A1 (en) 2000-12-22 2008-08-20 Dana-Farber Cancer Institute Regulation of cell growth by MUC1
EP1622648B1 (en) * 2003-03-24 2010-06-30 The Scripps Research Institute Dna vaccines against tumor growth and methods of use thereof
US7696306B2 (en) 2003-07-11 2010-04-13 Board of Agents of the University of Nebraska Compositions and methods for preventing or treating cancer
US8129506B2 (en) 2003-10-24 2012-03-06 Genzyme Corporation Modulation of the interaction of MUC1 with MUC1 ligands
WO2008097844A2 (en) 2007-02-02 2008-08-14 Dana -Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by muc1 and bh3- containing proapoptotic proteins
US7972870B2 (en) 2007-02-02 2011-07-05 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3
CN106279435B (zh) * 2016-08-16 2019-06-07 新乡医学院 靶向VEGF与mucin1的抗肿瘤疫苗、编码基因、表达载体、表达工程菌及应用
CN114230655A (zh) * 2021-03-24 2022-03-25 深圳市新靶向生物科技有限公司 一种与食道癌驱动基因突变相关的抗原肽组合及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1262545B (it) * 1993-10-25 1996-07-02 Menarini Ricerche Sud S P A A Sistema di espressione per linee cellulari eucariotiche
AU727308B2 (en) * 1997-02-24 2000-12-07 Dana-Farber Cancer Institute Recombinant pox virus for immunization against muc1 tumor-associated antigen

Also Published As

Publication number Publication date
PL348156A1 (en) 2002-05-06
JP2002528519A (ja) 2002-09-03
TR200101141T2 (tr) 2001-09-21
MXPA01004186A (es) 2002-06-04
AR020927A1 (es) 2002-06-05
SK5712001A3 (en) 2002-04-04
EP1124956A2 (en) 2001-08-22
CO5231134A1 (es) 2002-12-27
PE20001287A1 (es) 2000-12-07
IT1303683B1 (it) 2001-02-23
AU1152200A (en) 2000-05-22
BG105458A (en) 2002-06-28
ITMI982330A0 (it) 1998-10-30
ITMI982330A1 (it) 2000-04-30
CZ20011521A3 (cs) 2001-10-17
EA200100395A1 (ru) 2001-10-22
HUP0103784A2 (hu) 2002-02-28
WO2000025827A2 (en) 2000-05-11
WO2000025827A3 (en) 2000-08-10
CN1324406A (zh) 2001-11-28
CA2348745A1 (en) 2000-05-11

Similar Documents

Publication Publication Date Title
BR9907259A (pt) Compostos para terapia e diagnóstico de câncer de pulmão e processos para o seu uso
NO20084906L (no) DNA-sekvens som koder for tumornekrosefaktorrelatert ligand (TRELL), vertsorganisme transformert med slikt DNA samt TRELL, fremstilling og anvendelse derav ved fremstilling av medikamenter og antistoffer
BR0009505A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
BR9914892A (pt) Composição farmacêutica, contendo fragmentos de um dna de codificação de proteìna antigênica dotado com efeito antitumor
BR0012069A (pt) Composições e métodos para a terapia e diagnóstico de câncer pulmonar
BR0113491A (pt) Polinucleotìdeo e polipeptìdeo isolados, vetor de expressão, célula hospedeira, proteìna de fusão, métodos para estimular e/ou expandir células t especìficas para uma protéina de tumor, para estimular uma resposta imune em um paciente, para o tratamento de um câncer em um paciente e para inibir o desenvolvimento de um câncer em um paciente, população de célula t isolada, composição, e, uso de um componente.
BR0107643A (pt) Composições e processos para a terapia e diagnóstico de c ncer de próstata
BR9808881A (pt) Compostos para imunoterapia de câncer de próstata e métodos para seu uso
BR0316435A (pt) Produtos genéticos expressos diferencialmente em tumores e uso dos mesmos
EP0168214A3 (en) Tumor necrosis factor, methods for its preparation, compositions containing it, dna encoding it and assay method using such dna
ATE229977T1 (de) Peptide mit antiproliferativen eigenschaften
DE69534720D1 (de) Neuronales apotose-inhibitor protein, gen sequenz und mutationen die wirbelsäulenmuskelatrophie verursachen
BR9905111A (pt) Proteìnas de actinobacillus pleuropneumoniae
FI972170A (fi) Peptidejä, jotka kykenevät sitoutumaan GAP-proteiinin SH3-domeeniin, näitä peptidejä koodittavia nukleotidisekvenssejä, niiden valmistus ja käyttö
BR0207704A (pt) Alfa interferon modificado com imunogenicidade reduzida
BR9708005A (pt) C3 convertase resistente à regulação para baixo
BR9916549A (pt) Composição farmacêutica, vacina, proteìna, e, método para a prevenção ou tratamento de leishmaniose em um humano ou animal
BR0111024A (pt) Composições e métodos para a terapia e diagnóstico de câncer de mama
BR9809942A (pt) Moduladores de vias intracelulares de inflamação, morte celular e sobrevivência celular
IT1294967B1 (it) Composizione immunogenica da tlp
BR9713248A (pt) Sequência de nucleotìdeos e de proteìnas de mamastatina e processos de uso
SG148195A1 (en) Plasmids coding for p185neu protein sequence variants and therapeutic uses thereof
BR9510323A (pt) Variante de dnase i humana ácido nucleico isolado método para tratamento de um paciente tendo uma desordem ou doença pulmonar e composição farmacêutica
EE9900464A (et) Kõhre maatriksi oligomeerse valgu kasutamine reumatoidartriidi raviks
ATE374260T1 (de) Asthma-assoziiertes gen

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1913 DE 04/09/2007.